XtalPi and Pulin Bio Announce Strategic Collaboration to Empower Specialized and Innovative Blood Products with AI Technologies

To further implement the "Artificial Intelligence+"Acting with cutting-edge technologies to drive continuous innovation in the industry, XtalPi is committed to assisting the digital and intelligent transformation and upgrading of the biopharmaceutical sector. By integrating artificial intelligence, robotic experimentation, and other innovative technologies, and aligning with industrial implementation needs, XtalPi consistently enhances the core competitiveness of biopharmaceutical companies as well as specialized and innovative enterprises, promoting the deep integration of artificial intelligence and the real economy."

Recently, XtalPi (Stock Code:2228.HK) has signed a strategic cooperation agreement with Pacific Shuanglin Bio-pharmacy Co., Ltd. (stock code: 000403), a listed company in the blood products sector. The collaboration will fully leverage XtalPi's leading advantages in artificial intelligence technology and Pacific Shuanglin’s professional expertise in the blood products field. The two parties will cooperate in areas such as new product development and intelligent management of production quality, jointly promoting technological innovation and high-quality development in the blood products industry.The cooperation period is 5 years, with an estimated total scale of approximately 100 million RMB.

XtalPi Holdings Limited Chairman Shuhaotem Wen (front row, left one), Pacific Shuanglin Bio-pharmacy Co.,Ltd. Chairman Hao Li (front row, left two)

Attended the signing ceremony with corporate representatives

This strategic cooperation focuses on three core directions. The first is drug research and development and optimization, accelerating the R&D of blood products and other drugs, shortening the product’s time to market, and reducing R&D costs. The second is intelligent management of drug production and quality, providing intelligent management solutions covering the entire life cycle of production and quality management of blood products, including but not limited to automation and intelligent applications in the production process, as well as automation and intelligent applications in quality management laboratories and testing. The third is research on protein structure and function, offering functional analysis of existing plasma protein products, simulation analysis of protein structures and functions in plasma, etc., promoting the upgrading of blood products and the development of market applications.

Pacific Shuanglin Bio-pharmacy Co., Ltd. is a biotechnology enterprise that has long been committed to becoming an industry leader, firmly adhering to the business philosophy of "Smart Wins the Future." It hopes that this strategic cooperation will accelerate the speed of product development, reduce product development costs, deeply explore the application value of plasma protein products, build an intelligent management solution for the entire life cycle of production and quality management of blood products, expedite the company’s growth and intelligent strategy upgrade, and jointly open a new chapter in the integration and development of blood product enterprises with artificial intelligence.

Since its establishment, XtalPi has been committed to solving the industry challenges of "high cost, long cycle, and low success rate" in drug research and development by integrating artificial intelligence, quantum physics, and robotics technologies. We deeply understand that technology can only truly create value when it is rooted in the industrial ecosystem. In this collaboration, XtalPi will leverage its intelligent and automated platform advantages, forming a closed loop with Pacific Shuanglin Bio-pharmacy Co., Ltd.'s industrialization capabilities, jointly accelerating the development of innovative therapies.

● CloseInPacific Shuanglin Bio-pharmacy Co.,Ltd. ● 

Pacific Shuanglin Bio-pharmacy Co., Ltd. is a publicly listed company specializing in the research, development, production, and sales of blood products. Its products are made from the plasma of healthy individuals and plasma from specially immunized individuals, serving as critical strategic reserves and emergency medicines for major diseases in China. The company owns two core subsidiaries: Guangdong Shuanglin and Paisifeike. Guangdong Shuanglin is the largest high-tech enterprise for blood products in Guangdong Province and a national-level specialized and innovative "little giant" enterprise. Paisifeike is the only high-tech enterprise in Northeast China with a complete range of three major types of blood products and a provincial-level specialized and innovative enterprise. Pacific Shuanglin Bio-pharmacy has 11 product varieties, ranking third in the industry, and operates 38 plasma stations, also ranking third in the industry. It is a leading publicly listed company in the blood products sector capable of producing over 1,000 tons annually.